Omalizumab: A recombinant humanized monoclonal IgE-blocking antibody

Dermatology Online Journal

Volumn 11, Issue 1, 2005, Pages

  Scheinfeld, Noah ^a  

^a St Luke Roosevelt Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OMALIZUMAB; RECOMBINANT ANTIBODY; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN E; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY;

ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; BODY WEIGHT; CAT; CLINICAL TRIAL; DERMATOPHAGOIDES; DOG; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; ERYTHEMA; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; MOULD; NAUSEA; PEANUT ALLERGY; PHARYNGITIS; RASH; REVIEW; SINUSITIS; SKIN TEST; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; DRUG EFFECT; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS;

EID: 33745149044     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001 Aug;108(2):E36.
2. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147-54.
3. Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, Kamin W, Berg AV, Wahu U, Zielen S. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004;34:1079-85.
4. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, Zielen S, Bez, Friedrichs F, Von Berg A, Gerhold K, Hamelmann E, Hultsch, Kuehr J.The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;110:728-35.
5. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV. The Effects of Anti-IgE (Omalizumab) on Airways Inflammation in Allergic Asthma. Am J Respir Crit Care Med. 2004;170:583-93.
6. Feuchtinger T, Bartz H, von Berg A, Riedinger F, Brauburger J, Stenglein S, Wahn U, Schauer U. Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. Allergy Clin Immunol. 2003;111:428-30.
7. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131:46-52.
8. http://www.fda.gov/cder/biologics/ products/omalgen062003.htm (December 19, 2004).
9. Chung KF.Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma. Expert Opin Pharmacother. 2004;5:439-46.
10. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, Della Cioppa G, Gupta N. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:323-9.
11. Bang LM, Plosker GL Omalizumab: a review of its use in the management of allergic asthma. Treat Respir Med. 2004;3:183-99.
12. www.clevelandclinicmeded.com/medical_info/pharmacy/janfeb2004/omalizumab. htm (December 19, 2004).
13. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01236.html
14. Walker S, Monteil M, Phelan K, Lasserson T, Walters E. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;3:CD003559.
15. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, Trunet P. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004;113:360-1.
16. Milgrom H. Is there a role for treatment of asthma with omalizumab? Arch Dis Child. 2003;88:71-4.
17. Mittermann I, Aichberger KJ, Bunder R, Mothes N, Renz H, Valenta R. Autoimmunity and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2004;4:367-71.
18. Laske N, Bunikowski R, Niggemann B. Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann Allergy Asthma Immunol. 2003;91:202-4.
19. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. Allergy Clin Immunol. 2003;112:252-62.